Figure 7.
In vivo antifibrogenic activity of APNH NTs. (A) Schematic diagram showing the induction of hepatic fibrosis by CCl4 in mice and the administration with different formulations for therapy. (B) Immunofluorescence of HIF-1α in liver tissue sections. Nuclei were counterstained with DAPI. (C) Apoptotic cells in the liver tissue sections stained using a TUNEL assay. (D) Representative H&E-stained liver tissue sections. Micrographs showing hepatic collagen content visualized using (E) Sirius Red and (F) Masson's trichrome staining. Immunohistochemical staining of (G) α-SMA and (H) collagen-I. Scale bars, 100 μm. G1: control (healthy mice), G2: model (fibrotic mice), G3: Ag@Pt NTs (5 mg/kg), G4: NIL (0.2 mg/kg), G5: APNH NTs (5 mg/kg), and G6: APNH NTs (10 mg/kg). Data are shown as the mean ± SD (n = 3). NS (no significance), ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.